Skip to main content

Table 2 Event rates for outcomes in study cohorts, overall and within hemoglobin strata

From: Anemia and mortality in patients with nondialysis-dependent chronic kidney disease

 

Baseline ESA Nonusers

Baseline ESA Users

ESA Naives

Hb 8–10 g/dL

Hb 10.1–10.5 g/dL

Hb >10.5 g/dL

All

Hb 8–11 g/dL

Hb 11.1–12.5 g/dL

All

Hb 8–10 g/dL

Hb >10 g/dL

All

(N = 761)

(N = 780)

(N = 30,658)

(N = 32,199)

(N = 79)

(N = 30)

(N = 109)

(N = 193)

(N = 73)

(N = 266)

eGFR, mL/min/1.73m2, mean ± SD

40.3 ± 12.6

40.5 ± 11.8

48.3 ± 9.1

47.9 ± 9.4

27.0 ± 11.6

32.8 ± 12.0

28.6 ± 11.9

26.9 ± 11.6

29.5 ± 11.5

27.6 ± 11.6

MACE

 Event n

283

226

5788

6297

28

8

36

55

22

77

 Pt-year

1345

1552

68,321

71,218

125

59

183

209

89

298

 Mean follow-up, years

1.77

1.99

2.23

2.21

1.58

1.95

1.68

1.08

1.22

1.12

 Rate per 100 pt-year (95% CI)

21.04 (18.73, 23.64)

14.56 (12.78, 16.59)

8.47 (8.26, 8.69)

8.84 (8.63, 9.06)

22.45 (15.50, 32.51)

13.66 (6.83, 27.31)

19.64 (14.17, 27.23)

26.32 (20.20, 34.28)

24.67 (16.24, 37.46)

25.82 (20.65, 32.28)

MACE+

 Event n

369

301

7515

8185

40

15

55

80

32

112

 Pt-year

1203

1428

65,674

68,305

106

48

154

178

78

257

 Mean follow-up, years

1.58

1.83

2.14

2.12

1.34

1.61

1.42

0.92

1.07

0.97

 Rate per 100 pt-year (95% CI)

30.66 (27.69, 33.95)

21.08 (18.83, 23.60)

11.44 (11.19, 11.70)

11.98 (11.73, 12.25)

37.78 (27.71, 51.51)

30.98 (18.68, 51.38)

35.65 (27.37, 46.43)

44.84 (36.02, 55.83)

40.85 (28.89, 57.77)

43.62 (36.25, 52.50)

Death

 Event n

190

136

2573

2899

20

6

26

32

10

42

 Pt-year

1533

1734

73,529

76,796

142

61

202

235

102

337

 Mean follow-up, years

2.01

2.22

2.40

2.39

1.79

2.03

1.86

1.22

1.40

1.27

 Rate per 100 pt-year (95% CI)

12.39 (10.75, 14.28)

7.84 (6.63, 9.28)

3.50 (3.37, 3.64)

3.77 (3.64, 3.91)

14.12 (9.11, 21.88)

9.87 (4.43, 21.97)

12.84 (8.74, 18.86)

13.63 (9.64, 19.27)

9.82 (5.28, 18.24)

12.48 (9.22, 16.88)

MI

 Event n

109

107

2587

2803

15

2

17

32

7

39

 Pt-year

1441

1629

70,796

73,866

128

59

187

216

96

312

 Mean follow-up, years

1.89

2.09

2.31

2.29

1.62

1.96

1.71

1.12

1.31

1.17

 Rate per 100 pt-year (95% CI)

7.57 (6.27, 9.13)

6.57 (5.43, 7.94)

3.65 (3.52, 3.80)

3.79 (3.66, 3.94)

11.72 (7.06, 19.44)

3.41 (0.85, 13.63)

9.11 (5.66, 14.65)

14.78 (10.45, 20.90)

7.31 (3.48, 15.33)

12.49 (9.13, 17.09)

Stroke

 Event n

123

90

2840

3053

5

2

7

16

11

27

 Pt-year

1409

1632

70,395

73,436

138

61

199

224

94

319

 Mean follow-up, years

1.85

2.09

2.30

2.28

1.75

2.02

1.82

1.16

1.29

1.20

 Rate per 100 pt-year (95% CI)

8.73 (7.32, 10.42)

5.51 (4.49, 6.78)

4.03 (3.89, 4.19)

4.16 (4.01, 4.31)

3.62 (1.51, 8.70)

3.29 (0.82, 13.17)

3.52 (1.68, 7.38)

7.14 (4.37, 11.65)

11.65 (6.45, 21.03)

8.47 (5.81, 12.36)

CHF hospitalization

 Event n

261

224

4443

4928

31

14

45

66

23

89

 Pt-year

1291

1497

68,827

71,614

112

48

161

188

84

272

 Mean follow-up, years

1.70

1.92

2.24

2.22

1.42

1.62

1.47

0.98

1.15

1.02

 Rate per 100 pt-year (95% CI)

20.22 (17.91, 22.83)

14.97 (13.13, 17.06)

6.46 (6.27, 6.65)

6.88 (6.69, 7.08)

27.67 (19.46, 39.34)

28.88 (17.11, 48.77)

28.03 (20.93, 37.55)

35.05 (27.53, 44.61)

27.50 (18.27, 41.38)

32.73 (26.59, 40.28)

  1. Abbreviations: CHF congestive heart failure, CI confidence interval, CKD chronic kidney disease, ESA erythropoiesis-stimulating agent, Hb hemoglobin; hosp hospitalization, MI myocardial infarction, MACE major adverse cardiovascular events, n event count, pt patient, PVD peripheral vascular disease, SD standard deviation, yr year. Event rates 95% confidence intervals are based on exact Poisson estimates. In the case that an exact Poisson regression failed, normal approximation was used. Primary analysis, intent-to-treat
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us